Efficacy and safety of canakinumab in patients with Adult-Onset Still’s Disease: Results from an open-label Phase III study in Japan

Puntos clave

• The research aims to evaluate the efficacy and safety of canakinumab in treating patients with Adult-Onset Still's Disease (AOSD).
• Conducted an open-label Phase III study
• Focused on Japanese patients with AOSD
• Assessed various efficacy outcome measures at week 28
• Week 28 analysis showed improvements in multiple efficacy outcome measures
• No unexpected safety signals were reported